Coo And Co-Founder
CurrentCurrent drug discovery paradigm is ineffective with more than 90% of drugs failing to progress through all clinical stages of drug development. Principal reason for this high attrition rate is the excessive reliance on cellular models which are clinically less relevant. Nobel prize winning cellular reprogramming technology has the potential to transform the drug discovery landscape by employing patient derived induced pluripotent stem cells (iPSC) at the earliest stages, thus drastically reducing clinical trial failure. However, generating iPSCs is labour intensive and costly, which has been a major bottleneck in realising its full potential. We at Oxford StemTech have developed a novel method of producing high quality iPSC lines at scale and at a fraction of cost currently possible. iPSC technologies if combined with other technologies such as gene editing, organoids and artificial intelligence can truly revolutionize drug discovery, bringing precision medicine in the clinic earlier than previously imagined. Join the purpose!